Biogen on aducanumab: ‘We’re ready for an immediate launch’ Biogen expects to begin shipping Aduhelm (aducanumab-avwa) in two weeks: after the FDA granted the Alzheimer s drug accelerated approval on Monday.
There are around 900 sites across the US ready to implement treatment, including clinical trial centers and others with the necessary infrastructure to diagnose and treat patients.
Initial supply will come from Biogen’s Research Triangle Park (RTP) in North Carolina: but Biogen eyes up global potential for the drug with its Solothurn, Switzerland facility leading supply.
The monoclonal antibody, branded as Aduhelm, was
granted accelerated approval for the treatment of Alzheimer s by the FDA earlier this week: making it the first drug for the diseases approved since 2003. It is the first therapy to target the underlying diseases process of Alzheimers, unlike other available therapies which only treat symptoms.